[go: up one dir, main page]

ES2330071A1 - Combination of active substances. (Machine-translation by Google Translate, not legally binding) - Google Patents

Combination of active substances. (Machine-translation by Google Translate, not legally binding) Download PDF

Info

Publication number
ES2330071A1
ES2330071A1 ES200800079A ES200800079A ES2330071A1 ES 2330071 A1 ES2330071 A1 ES 2330071A1 ES 200800079 A ES200800079 A ES 200800079A ES 200800079 A ES200800079 A ES 200800079A ES 2330071 A1 ES2330071 A1 ES 2330071A1
Authority
ES
Spain
Prior art keywords
combination
active substances
translation
machine
legally binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200800079A
Other languages
Spanish (es)
Other versions
ES2330071B1 (en
Inventor
Maria Angeles Fisas Escasany
Helmut H. Buschmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07384007A external-priority patent/EP1946777A1/en
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2330071A1 publication Critical patent/ES2330071A1/en
Application granted granted Critical
Publication of ES2330071B1 publication Critical patent/ES2330071B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combination of active substances. The present invention relates to a combination of active substances comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight gain as a side effect, a medicament comprising said combination of active substances, a pharmaceutical formulation comprising said combination of active substances and the use of said combination of active substances for the manufacture of a medicament. (Machine-translation by Google Translate, not legally binding)
ES200800079A 2007-01-15 2008-01-14 COMBINATION OF ACTIVE SUBSTANCES. Expired - Fee Related ES2330071B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07000745 2007-01-15
EP07000745 2007-01-15
EP07384007A EP1946777A1 (en) 2007-01-16 2007-01-16 Substituted pyrazoline for preventing weight gain
EP07384007 2007-01-16

Publications (2)

Publication Number Publication Date
ES2330071A1 true ES2330071A1 (en) 2009-12-03
ES2330071B1 ES2330071B1 (en) 2010-07-05

Family

ID=41327361

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200800079A Expired - Fee Related ES2330071B1 (en) 2007-01-15 2008-01-14 COMBINATION OF ACTIVE SUBSTANCES.

Country Status (1)

Country Link
ES (1) ES2330071B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
FR2882931A1 (en) * 2005-03-14 2006-09-15 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION AN ANTAGONIST COMPOUND OF CANNABINOIDESS RECEPTORS AND AN ANTIPSYCHOTIC AGENT

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074920A1 (en) * 2004-01-30 2005-08-18 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005077911A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US20060189658A1 (en) * 2004-02-17 2006-08-24 Laboratorios Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
FR2882931A1 (en) * 2005-03-14 2006-09-15 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION AN ANTAGONIST COMPOUND OF CANNABINOIDESS RECEPTORS AND AN ANTIPSYCHOTIC AGENT

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GOBSHTIS, N. et al. "{}Antidepressant-induced undesirable weigth gain: Prevention with rimonabant without interference with behavioral effectiveness"{}. European Journal of Pharmacology 2007, Volumen 554, páginas 155-163. [Disponible en línea el 19 de Octubre de 2006]. Ver página 155, resumen. *
GOBSHTIS, N. et al. "Antidepressant-induced undesirable weigth gain: Prevention with rimonabant without interference with behavioral effectiveness". European Journal of Pharmacology 2007, Volumen 554, páginas 155-163. [Disponible en línea el 19 de Octubre de 2006]. Ver página 155, resumen. *
LANGE, J.H.M. & KRUSE, C.G. "{}Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists"{}. Drug Discovery Today 2005, Volumen 10, Número 10, páginas 693-702. Ver página 696, columna 1, párrafo 4 - página 697, columna 2, párrafo 2; página 699, figura 4; página 700, columna 2, párrafo 2. *
LANGE, J.H.M. & KRUSE, C.G. "Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists". Drug Discovery Today 2005, Volumen 10, Número 10, páginas 693-702. Ver página 696, columna 1, párrafo 4 - página 697, columna 2, párrafo 2; página 699, figura 4; página 700, columna 2, párrafo 2. *
LANGE, J.H.M. et al. "{}Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists"{}. Journal of Medicinal Chemistry 2005, Volumen 48, páginas 1823-1838. Ver página 1823, resumen; página 1824, figura 1; página 1828, columna 2. *
LANGE, J.H.M. et al. "Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists". Journal of Medicinal Chemistry 2005, Volumen 48, páginas 1823-1838. Ver página 1823, resumen; página 1824, figura 1; página 1828, columna 2. *

Also Published As

Publication number Publication date
ES2330071B1 (en) 2010-07-05

Similar Documents

Publication Publication Date Title
MA32383B1 (en) Indazole derivatives with phenyl and benzodoxynil alternatives
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
BRPI0821004A8 (en) AMINOPYRAZOLE DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND USE OF IT
MX358617B (en) FORMULATIONS OF DPP INHIBITORS IV.
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MA32200B1 (en) New formulations, tablets consisting of these formulas, their use and method of preparation
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
BRPI0915084B8 (en) compound, and, pharmaceutical composition
MY149622A (en) Pyrazoles as 11-beta-hsd-1
EA021275B9 (en) Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
EA201170198A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA109421C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING SIGMA-RECEPTOR LIGANDS
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
IN2012DN02139A (en)
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
JO3577B1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt
ATE487720T1 (en) 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
MX2009010374A (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments.
CR20110704A (en) COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
MY163762A (en) Therapeutic agent for chronic renal failure
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20091203

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2330071B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20161207